Xuebin Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xuebin Li has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Feng Ze
Department of Cardiac Electrophysiology, Peking University People’s Hospital, Beijing, China
5 shared publicationsXu Zhou
Department of Cardiac Electrophysiology, Peking University People’s Hospital, Beijing, China
5 shared publicationsDing Li
Department of Cardiac Electrophysiology, Peking University People’s Hospital, Beijing, China
4 shared publicationsJinshan He
Department of Cardiac Electrophysiology, Peking University People’s Hospital, Beijing, China
3 shared publicationsLong Wang
Department of Cardiac Electrophysiology, Peking University People’s Hospital, Beijing, China
3 shared publicationsCuizhen Yuan
Department of Cardiac Electrophysiology, Peking University People’s Hospital, Beijing, China
2 shared publications
Latest Publications
- Open Access
Effect of acupuncture on quality of life in atrial fibrillation: study protocol for a randomised controlled trial
Introduction Atrial fibrillation (AF) is the prevalent cardiac arrhythmia and can significantly impair the quality of life (QoL). Although catheter ablation (CA) is an established treatment for AF,post-procedural complications or perceived inadequate control of AF may diminish the QoL for some patients, potentially even to levels lower than pre-procedure. Preliminary findings from our previous pilot trial indicate that acupuncture may positively influence QoL in AF patients post-CA. This study aims to increase the sample size to evaluate the efficacy of acupuncture as an adjunctive treatment to conventional medical therapy in improving QoL of patients with AF after CA. Methods and design This multicentre randomised clinical trial will be conducted in China. A total of 146 eligible patients will be randomly assigned in a 1:1 ratio to either the acupuncture group or the sham acupuncture group. All patients will receive standard postablation care and undergo 18 sessions of acupuncture/sham acupuncture within 12 weeks following CA, followed by a 9-month follow-up period. The primary outcome is the change in the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) summary score from baseline to months 6 after CA. Secondary outcomes include the changes in the AFEQT subscale scores at months 6, the AFEQT summary and subscale score at months 3 and 12, AF burden, AF recurrence, heart rate variability, number of cardioversions, repeat CA procedures, European Heart Rhythm Association score, number of arrhythmia-related hospitalisations, average heart rate, use of Six-Dimensional Health State Short Form to assess health status, costs incurred by disease treatment, Credibility/Expectancy Questionnaire and blinded assessments. Adverse events will also be meticulously recorded throughout the trial. Ethics and dissemination Ethics approval has been granted by the Ethics Committee of Beijing University of Traditional Chinese Medicine (approval no: 2020BZYLL0802) and seven other subcentres. The findings of the study results will be disseminated through presentations at scientific conferences or publications in peer-reviewed journals. Trial registration number ChiCTR2100049323.
Open AccessEffect of acupuncture on quality of life in atrial fibrillation: study protocol for a randomised controlled trial
Introduction Atrial fibrillation (AF) is the prevalent cardiac arrhythmia and can significantly impair the quality of life (QoL). Although catheter ablation (CA) is an established treatment for AF,post-procedural complications or perceived inadequate control of AF may diminish the QoL for some patients, potentially even to levels lower than pre-procedure. Preliminary findings from our previous pilot trial indicate that acupuncture may positively influence QoL in AF patients post-CA. This study aims to increase the sample size to evaluate the efficacy of acupuncture as an adjunctive treatment to conventional medical therapy in improving QoL of patients with AF after CA. Methods and design This multicentre randomised clinical trial will be conducted in China. A total of 146 eligible patients will be randomly assigned in a 1:1 ratio to either the acupuncture group or the sham acupuncture group. All patients will receive standard postablation care and undergo 18 sessions of acupuncture/sham acupuncture within 12 weeks following CA, followed by a 9-month follow-up period. The primary outcome is the change in the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) summary score from baseline to months 6 after CA. Secondary outcomes include the changes in the AFEQT subscale scores at months 6, the AFEQT summary and subscale score at months 3 and 12, AF burden, AF recurrence, heart rate variability, number of cardioversions, repeat CA procedures, European Heart Rhythm Association score, number of arrhythmia-related hospitalisations, average heart rate, use of Six-Dimensional Health State Short Form to assess health status, costs incurred by disease treatment, Credibility/Expectancy Questionnaire and blinded assessments. Adverse events will also be meticulously recorded throughout the trial. Ethics and dissemination Ethics approval has been granted by the Ethics Committee of Beijing University of Traditional Chinese Medicine (approval no: 2020BZYLL0802) and seven other subcentres. The findings of the study results will be disseminated through presentations at scientific conferences or publications in peer-reviewed journals. Trial registration number ChiCTR2100049323.
- Open Access
- 30 June 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 892122
Initial Experience in Transvenous Implantation of a Left Ventricular Lead With a Novel Venogram Balloon Catheter
Aim: The most challenging and time-consuming stage of cardiac resynchronization therapy (CRT) device implantation is coronary sinus (CS) cannulation and left ventricular epicardial electrode implantation. This paper reports the initial clinical experience of CS cannulation and left ventricular lead implantation guided by a novel venogram balloon catheter (Lee’s venogram balloon catheter).Methods and Results: Consecutive patients eligible for CRT were deemed suitable for this novel venogram balloon catheter. Parameters such as left ventricular lead implantation time, procedure time, and fluoroscopy time were recorded. CS cannulation with LV lead implantation guided by Lee’s venogram balloon catheter was successful in all 5 patients, including 4 challenging cases. The total fluoroscopy and procedural durations were 5.0 ± 3.0 and 57.4 ± 12.5 min, respectively. No adverse catheter-related events occurred during the procedures.Conclusion: This initial study of an innovative venogram balloon catheter demonstrated that it greatly facilitated CS cannulation and successful LV lead placement in all patients undergoing CRT system implantation. This significantly shortened the learning curve and showed a decrease in left ventricular lead implantation time, procedure time, and fluoroscopy time.
- 30 June 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 892122
Open AccessInitial Experience in Transvenous Implantation of a Left Ventricular Lead With a Novel Venogram Balloon Catheter
Aim: The most challenging and time-consuming stage of cardiac resynchronization therapy (CRT) device implantation is coronary sinus (CS) cannulation and left ventricular epicardial electrode implantation. This paper reports the initial clinical experience of CS cannulation and left ventricular lead implantation guided by a novel venogram balloon catheter (Lee’s venogram balloon catheter).Methods and Results: Consecutive patients eligible for CRT were deemed suitable for this novel venogram balloon catheter. Parameters such as left ventricular lead implantation time, procedure time, and fluoroscopy time were recorded. CS cannulation with LV lead implantation guided by Lee’s venogram balloon catheter was successful in all 5 patients, including 4 challenging cases. The total fluoroscopy and procedural durations were 5.0 ± 3.0 and 57.4 ± 12.5 min, respectively. No adverse catheter-related events occurred during the procedures.Conclusion: This initial study of an innovative venogram balloon catheter demonstrated that it greatly facilitated CS cannulation and successful LV lead placement in all patients undergoing CRT system implantation. This significantly shortened the learning curve and showed a decrease in left ventricular lead implantation time, procedure time, and fluoroscopy time.
- 2 May 2022
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 45 (6) , 761-767
Bridge pacemaker with an externalized active fixation lead for pacemaker‐dependent patients with device infection
Background The risk of Cardiac Implantable Electronic Device (CIED) infection has been increasing in recent years. For pacemaker-dependent patients, a temporary pacemaker is needed before a new device can be implanted. The aim of this study is to evaluate the safety and efficacy of using a temporary pacing device with an externalized active fixation lead (bridge pacemaker) before a new device can be implanted in pacemaker-dependent patients with device infection. Methods All patients who were admitted to our cardiac center with CIED infection and in need of bridge pacemaker implantation from April 2013 to August 2020 were prospectively enrolled in this observational study. The medical records of all patients were collected and evaluated. All procedure-related complications were also collected. Long-term outcomes, including reinfection and death within 1 year after hospital discharge, were collected through telephone follow-ups. Results During the study period, 1050 patients underwent CIED extraction, of which 312 pacemaker-dependent patients underwent bridge pacemaker implantation. The mean age of the extracted leads was 44 +/- 38.7 months. The bridge pacemakers were in use for a mean duration of 6 days. Nine patients developed procedure-related complications including pericardial tamponade, pneumothorax, peripheral venous thrombosis, and pulmonary embolism. Three patients developed complications that were related to their bridge pacemakers, including lead dislodgement, over-sensing and elevated pacing threshold. During the 1-year follow-up, it was found that four patients had developed CIED reinfection and three patients had died due to cardiac-related reasons. Conclusions A bridge pacemaker with an externalized active fixation lead is safe and efficacious for pacemaker-dependent patients with device infection.
- 2 May 2022
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 45 (6) , 761-767
Bridge pacemaker with an externalized active fixation lead for pacemaker‐dependent patients with device infection
Background The risk of Cardiac Implantable Electronic Device (CIED) infection has been increasing in recent years. For pacemaker-dependent patients, a temporary pacemaker is needed before a new device can be implanted. The aim of this study is to evaluate the safety and efficacy of using a temporary pacing device with an externalized active fixation lead (bridge pacemaker) before a new device can be implanted in pacemaker-dependent patients with device infection. Methods All patients who were admitted to our cardiac center with CIED infection and in need of bridge pacemaker implantation from April 2013 to August 2020 were prospectively enrolled in this observational study. The medical records of all patients were collected and evaluated. All procedure-related complications were also collected. Long-term outcomes, including reinfection and death within 1 year after hospital discharge, were collected through telephone follow-ups. Results During the study period, 1050 patients underwent CIED extraction, of which 312 pacemaker-dependent patients underwent bridge pacemaker implantation. The mean age of the extracted leads was 44 +/- 38.7 months. The bridge pacemakers were in use for a mean duration of 6 days. Nine patients developed procedure-related complications including pericardial tamponade, pneumothorax, peripheral venous thrombosis, and pulmonary embolism. Three patients developed complications that were related to their bridge pacemakers, including lead dislodgement, over-sensing and elevated pacing threshold. During the 1-year follow-up, it was found that four patients had developed CIED reinfection and three patients had died due to cardiac-related reasons. Conclusions A bridge pacemaker with an externalized active fixation lead is safe and efficacious for pacemaker-dependent patients with device infection.
- Open Access
- 22 March 2022
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2022, 1-23
Research Progress on Natural Products’ Therapeutic Effects on Atrial Fibrillation by Regulating Ion Channels
Antiarrhythmic drugs (AADs) have a therapeutic effect on atrial fibrillation (AF) by regulating the function of ion channels. However, several adverse effects and high recurrence rates after drug withdrawal seriously affect patients’ medication compliance and clinical prognosis. Thus, safer and more effective drugs are urgently needed. Active components extracted from natural products are potential choices for AF therapy. Natural products like Panax notoginseng (Burk.) F.H. Chen, Sophora flavescens Ait., Stephania tetrandra S. Moore., Pueraria lobata (Willd.) Ohwi var. thomsonii (Benth.) Vaniot der Maesen., and Coptis chinensis Franch. have a long history in the treatment of arrhythmia, myocardial infarction, stroke, and heart failure in China. Based on the classification of chemical structures, this article discussed the natural product components’ therapeutic effects on atrial fibrillation by regulating ion channels, connexins, and expression of related genes, in order to provide a reference for development of therapeutic drugs for atrial fibrillation.
- 22 March 2022
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2022, 1-23
Open AccessResearch Progress on Natural Products’ Therapeutic Effects on Atrial Fibrillation by Regulating Ion Channels
Antiarrhythmic drugs (AADs) have a therapeutic effect on atrial fibrillation (AF) by regulating the function of ion channels. However, several adverse effects and high recurrence rates after drug withdrawal seriously affect patients’ medication compliance and clinical prognosis. Thus, safer and more effective drugs are urgently needed. Active components extracted from natural products are potential choices for AF therapy. Natural products like Panax notoginseng (Burk.) F.H. Chen, Sophora flavescens Ait., Stephania tetrandra S. Moore., Pueraria lobata (Willd.) Ohwi var. thomsonii (Benth.) Vaniot der Maesen., and Coptis chinensis Franch. have a long history in the treatment of arrhythmia, myocardial infarction, stroke, and heart failure in China. Based on the classification of chemical structures, this article discussed the natural product components’ therapeutic effects on atrial fibrillation by regulating ion channels, connexins, and expression of related genes, in order to provide a reference for development of therapeutic drugs for atrial fibrillation.
- Open Access
- 17 June 2021
- Published by Wiley in Clinical Cardiology
- Vol. 44 (7) , 971-977
Efficacy and safety of transvenous lead extraction in the Chinese octogenarian patients
Background: Managing elderly patients with infection or malfunction deriving from a cardiac implantable electronic device (CIED) may be challenging. We report the safety and effectiveness of transvenous lead extraction in Chinese octogenarian patients.Hypothesis: Transvenous lead extraction can be performed safely and successfully in the Chinese octogenarians.Methods: We retrospectively identified all patients who underwent TLE at our institution between March 2013 and January 2021. This population was divided into the following two groups based solely on age: octogenarians and non‐octogenarians. These two groups were compared on the basis of several characteristics and clinical outcomes.Results: Consecutive 1106 patients were analyzed, including 184 (16.6%) octogenarians and 922(83.4%) non‐octogenarians. The octogenarians presented more comorbidities. A total of 378 leads and 2004 leads were removed from the patients in the octogenarian group and non‐octogenarian group, respectively. The mean lead implant duration was 6.1 ± 5.1 and 5.8 ± 4.6 years for octogenarians and non‐octogenarians (p = 0.296). The majority of the patients in both groups underwent TLE through the femoral approach (67.5% vs 61.6%, p = 0.14). The complete procedure success rate was similar between the octogenarian and non‐octogenarian group (96.7% vs.95.3%, p = 0.39). There were no differences with respect to the proportion of minor, major complications and deaths. Long‐term mortality (median time 3.3 years) after TLE in octogenarians was significantly higher compared with younger individuals.Conclusions: At experienced centers, transvenous lead extraction can be performed safely in Chinese octogenarians with procedural success rate and complication rate comparable to younger individuals.
- 17 June 2021
- Published by Wiley in Clinical Cardiology
- Vol. 44 (7) , 971-977
Open AccessEfficacy and safety of transvenous lead extraction in the Chinese octogenarian patients
Background: Managing elderly patients with infection or malfunction deriving from a cardiac implantable electronic device (CIED) may be challenging. We report the safety and effectiveness of transvenous lead extraction in Chinese octogenarian patients.Hypothesis: Transvenous lead extraction can be performed safely and successfully in the Chinese octogenarians.Methods: We retrospectively identified all patients who underwent TLE at our institution between March 2013 and January 2021. This population was divided into the following two groups based solely on age: octogenarians and non‐octogenarians. These two groups were compared on the basis of several characteristics and clinical outcomes.Results: Consecutive 1106 patients were analyzed, including 184 (16.6%) octogenarians and 922(83.4%) non‐octogenarians. The octogenarians presented more comorbidities. A total of 378 leads and 2004 leads were removed from the patients in the octogenarian group and non‐octogenarian group, respectively. The mean lead implant duration was 6.1 ± 5.1 and 5.8 ± 4.6 years for octogenarians and non‐octogenarians (p = 0.296). The majority of the patients in both groups underwent TLE through the femoral approach (67.5% vs 61.6%, p = 0.14). The complete procedure success rate was similar between the octogenarian and non‐octogenarian group (96.7% vs.95.3%, p = 0.39). There were no differences with respect to the proportion of minor, major complications and deaths. Long‐term mortality (median time 3.3 years) after TLE in octogenarians was significantly higher compared with younger individuals.Conclusions: At experienced centers, transvenous lead extraction can be performed safely in Chinese octogenarians with procedural success rate and complication rate comparable to younger individuals.
- Open Access
- 6 January 2020
- Published by Wiley in Clinical Cardiology
- Vol. 43 (4) , 386-393
Outcomes of transvenous lead extraction in patients with lead perforation: A single‐center experience
Background: Management of cardiac perforation caused by the lead of a cardiac implantable electronic device (CIED) is currently unclear. This study evaluated the outcomes of transvenous lead extraction (TLE) in patients with cardiac perforation caused by a transvenous lead.Hypothesis: Removal of perforated lead by transvenous approach is safe and effective.Methods: The medical records of all patients diagnosed with cardiac perforation by a pacing or defibrillator lead in Peking University People's Hospital from January 2008 to January 2019 were reviewed. We included patients who were managed by TLE.Results: A total of 53 patients (30 men; mean age: 67 ± 15 years) with lead perforation managed by TLE were included. Most of the perforated leads (94.9%) were pacemaker leads. Forty‐three leads (81.1%) were implanted within 1 year. Ten patients with a high risk of hemopericardium underwent percutaneous subxiphoid pericardial puncture prior to TLE. All 53 culprit leads were removed completely without major complications. Simple traction with or without a locking stylet was sufficient in 51 patients (96.2%). Forty‐eight patients (90.6%) had a new active‐fixation lead reimplanted. No patients showed evidence of new‐onset or worsening pericardial effusion during the procedure and hospital stay. During a median follow‐up time of 16 months, no recurrence of symptoms associated with lead perforation or CIED‐related infection were reported.Conclusion: In most patients with lead perforation, TLE can be a safe and effective management approach.
- 6 January 2020
- Published by Wiley in Clinical Cardiology
- Vol. 43 (4) , 386-393
Open AccessOutcomes of transvenous lead extraction in patients with lead perforation: A single‐center experience
Background: Management of cardiac perforation caused by the lead of a cardiac implantable electronic device (CIED) is currently unclear. This study evaluated the outcomes of transvenous lead extraction (TLE) in patients with cardiac perforation caused by a transvenous lead.Hypothesis: Removal of perforated lead by transvenous approach is safe and effective.Methods: The medical records of all patients diagnosed with cardiac perforation by a pacing or defibrillator lead in Peking University People's Hospital from January 2008 to January 2019 were reviewed. We included patients who were managed by TLE.Results: A total of 53 patients (30 men; mean age: 67 ± 15 years) with lead perforation managed by TLE were included. Most of the perforated leads (94.9%) were pacemaker leads. Forty‐three leads (81.1%) were implanted within 1 year. Ten patients with a high risk of hemopericardium underwent percutaneous subxiphoid pericardial puncture prior to TLE. All 53 culprit leads were removed completely without major complications. Simple traction with or without a locking stylet was sufficient in 51 patients (96.2%). Forty‐eight patients (90.6%) had a new active‐fixation lead reimplanted. No patients showed evidence of new‐onset or worsening pericardial effusion during the procedure and hospital stay. During a median follow‐up time of 16 months, no recurrence of symptoms associated with lead perforation or CIED‐related infection were reported.Conclusion: In most patients with lead perforation, TLE can be a safe and effective management approach.
- Open Access
- 26 December 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 7 (24) , 4327-4333
Percutaneous management of atrium and lung perforation: A case report
Cardiac perforation by a transvenous lead is an uncommon but serious complication. Delayed perforation, defined as migration and perforation of an implanted lead at least 1 mo after implantation, is exceedingly rare and prone to underdiagnosis, and its optimal management is currently unclear. We report an uneventful transvenous extraction of an active fixation lead that led to delayed perforation of the right atrium, pericardium, and lung, disclosed 2 mo after implantation. A 61-year-old woman with atrial lead perforation was transferred to our center. She had a dual-chamber pacemaker with active fixation leads implanted 8 mo previously. At 2 mo after implantation, she complained of chest pain and hemoptysis. Chest computed tomography revealed atrial lead migration into the lung. No pericardial or pleural effusion was detected. She underwent transvenous lead extraction in the electrophysiology room with surgical backup. The percutaneous subxiphoid pericardial puncture was performed first, and a pigtail catheter was left in the pericardial sac throughout the procedure. Then, a new active fixation lead was implanted at a different site with less tension. After the active screw was retracted, the culprit atrial lead was explanted successfully with simple traction. There were no complications during or after the procedure. The patient recovered well and follow-up was uneventful. Percutaneous management of perforated active fixation lead outside the pericardial sac under surgical backup is safe and effective.
- 26 December 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 7 (24) , 4327-4333
Open AccessPercutaneous management of atrium and lung perforation: A case report
Cardiac perforation by a transvenous lead is an uncommon but serious complication. Delayed perforation, defined as migration and perforation of an implanted lead at least 1 mo after implantation, is exceedingly rare and prone to underdiagnosis, and its optimal management is currently unclear. We report an uneventful transvenous extraction of an active fixation lead that led to delayed perforation of the right atrium, pericardium, and lung, disclosed 2 mo after implantation. A 61-year-old woman with atrial lead perforation was transferred to our center. She had a dual-chamber pacemaker with active fixation leads implanted 8 mo previously. At 2 mo after implantation, she complained of chest pain and hemoptysis. Chest computed tomography revealed atrial lead migration into the lung. No pericardial or pleural effusion was detected. She underwent transvenous lead extraction in the electrophysiology room with surgical backup. The percutaneous subxiphoid pericardial puncture was performed first, and a pigtail catheter was left in the pericardial sac throughout the procedure. Then, a new active fixation lead was implanted at a different site with less tension. After the active screw was retracted, the culprit atrial lead was explanted successfully with simple traction. There were no complications during or after the procedure. The patient recovered well and follow-up was uneventful. Percutaneous management of perforated active fixation lead outside the pericardial sac under surgical backup is safe and effective.
- 30 November 2019
- Published by Springer Nature in Heart and Vessels
- Vol. 35 (6) , 825-834
Transfemoral extraction of pacemaker and implantable cardioverter defibrillator leads using Needle’s Eye Snare: a single-center experience of more than 900 leads
The femoral approach with the Needle’s Eye Snare (NES) is often used for bailout after failure of the superior approach for transvenous lead extraction (TLE). The safety and efficacy of the NES as a first-line tool for TLE remain unclear. The medical records of patients who underwent TLE via the femoral approach utilizing the NES from May 2014 to June 2019 in Peking University People’s Hospital were retrospectively reviewed. Nine hundred and eighty-five leads were extracted in 492 patients (369 men; mean age 72.8 ± 29.0 years). The median (range) number of leads extracted per patient was 2 (1–6). The mean indwelling time of all extracted leads was 112.6 ± 52.0 months. The complete procedure success rate, clinical success rate, and failure rate were 94.1% (463/492), 97.8% (481/492), and 1.1% (11/492), respectively. Major complications including death occurred in nine patients (1.9%), of whom eight developed cardiac tamponade. Among these eight patients, emergency pericardiocentesis followed by rescue surgical repair if necessary was successful in 6 (75.0%) and failed in 2 (25.0%). No significant differences were found in the clinical success rate or major complications rate between patients with pacemakers and implantable cardioverter defibrillators, or between patients with infected and uninfected leads. A femoral approach with the NES is safe and effective for TLE of both pacing and defibrillator leads and could be considered a first-line approach. Cardiac tamponade was the most frequent cardiovascular complication. A strategy of emergency pericardiocentesis followed by a rescue surgical approach seems to be reasonable technique to treat a cardiac tamponade.
- 30 November 2019
- Published by Springer Nature in Heart and Vessels
- Vol. 35 (6) , 825-834
Transfemoral extraction of pacemaker and implantable cardioverter defibrillator leads using Needle’s Eye Snare: a single-center experience of more than 900 leads
The femoral approach with the Needle’s Eye Snare (NES) is often used for bailout after failure of the superior approach for transvenous lead extraction (TLE). The safety and efficacy of the NES as a first-line tool for TLE remain unclear. The medical records of patients who underwent TLE via the femoral approach utilizing the NES from May 2014 to June 2019 in Peking University People’s Hospital were retrospectively reviewed. Nine hundred and eighty-five leads were extracted in 492 patients (369 men; mean age 72.8 ± 29.0 years). The median (range) number of leads extracted per patient was 2 (1–6). The mean indwelling time of all extracted leads was 112.6 ± 52.0 months. The complete procedure success rate, clinical success rate, and failure rate were 94.1% (463/492), 97.8% (481/492), and 1.1% (11/492), respectively. Major complications including death occurred in nine patients (1.9%), of whom eight developed cardiac tamponade. Among these eight patients, emergency pericardiocentesis followed by rescue surgical repair if necessary was successful in 6 (75.0%) and failed in 2 (25.0%). No significant differences were found in the clinical success rate or major complications rate between patients with pacemakers and implantable cardioverter defibrillators, or between patients with infected and uninfected leads. A femoral approach with the NES is safe and effective for TLE of both pacing and defibrillator leads and could be considered a first-line approach. Cardiac tamponade was the most frequent cardiovascular complication. A strategy of emergency pericardiocentesis followed by a rescue surgical approach seems to be reasonable technique to treat a cardiac tamponade.